Search PubMed⌕ Search

Biomedical subjects

Fu-lin Tang

Publications and source records attributed to Fu-lin Tang.

18 recordsLinked to original sources
PubMed2005

[Prevalence of antiepithelial cell antibody in systemic vasculitis and identification of the target antigen thereof].

OBJECTIVE: To investigate the prevalence of antiepithelial cell antibody (AECA) in systemic vasculitis (SV) and the target antigen thereof. METHOD: Sera of 113 patients with SV of different kinds, 46 patients with Behcet's disease, 23 patients with Takayasu arteritis, 19 patients with Wegener's granulomatosis, 8 patients with polyarteritis nodosa, 7 patients with microscopic polyangiitis, and 10 patients with Churg-Strauss syndrome were collected to detect the protein expression of AECA by Western blotting, with the protein of the endothelial cells of the line EA. hy926 line as substrate. Two-dimensional electrophoresis combined with immunoblotting, liquid chromatography-electrospray ionization mass spectrography was used to detect the target antigens related to vasculitis. Sera of 57 patients with systemic lupus erythematosus (SLE), 25 patients with rheumatoid arthritis (RA), and 20 healthy persons were collected as controls. RESULTS: The AECA-positive rate of the SV patients was 69.0%, not significantly different from that of the SLE patients (66.7%), but significantly higher than those of the RA patients (6.7%, P < 0.01) and healthy persons (0, P < 0.01). The AECA from the SV patients reacted with the endothelial cell (EC) antigens with the molecular size of 26 to 125 kDa, and the AECA from the SLE patients reacted with the EC antigens with the molecular size of 15 to 97 kDa. The EC antigens with the molecular size of 47 kDa was commonly found in the sera of the AECA-positive SV patients and SLE patients, however, was not found in the RA, and polymyositis-dermatomyositis patients. The EC protein reacted by 47 kDa protein was identified by proteomic techniques as alpha-enolase. CONCLUSION: A group of heterogeneous antibodies, AECA can be found frequently in patients with SV and SLA. AECA reacts against a common EC antigen, alpha-enolase.

Adolescent↗
PubMed2005

[A study of antiendothelial cell antibodies in Behcet's disease].

OBJECTIVE: To investigate the clinical significant of antiendothelial cell antibodies (AECA) in Behcet's disease. METHODS: With human umbilical vein endothelial cell as substrate cell, sera from 59 Behcet's disease patients were detected for the presence of AECA by using fixed cell-ELISA. The associations of AECA to clinical disease activity were analyzed. In addition, Sera from other 70 systemic vasculitis (including 28 Takayasu arteritis, 20 Wegener's granulomatosis, 8 polyarteritis nodosa, 9 microscopic polyangiitis, 5 Churg-Strauss syndrome), 57 systemic lupus erythematosus (SLE), 25 rheumatoid arthritis and 85 healthy donors were screened for AECA. The associations of AECA to clinical disease activity were analyzed. RESULTS: The prevalence of AECA by human umbilical vein endothelial cell cell-ELISA was 47.5% in Behcet's disease. Compared with patients with rheumatoid arthritis (4.0%) and normal group (1.2%), AECA were more frequently found in patients with Behcet's disease, other systemic vasculitis (68.6%) and SLE (45.7%) (P < 0.01). The positive result on pathergy testing was more frequently found in AECA-positive patient with Behcet's disease (P < 0.05). After the treatment, patients with active disease entering remission showed a decrease in both AECA titers and the mean level of ESR (P < 0.05). CONCLUSIONS: AECA could be found more frequently in patients with Behcet's disease, associated closely with disease activity, which suggest that AECA may be used as an index in monitoring disease activity and effect of therapy in Behcet's disease. But AECA could also be found in other systemic vasculitis and SLE.

Adolescent↗
PubMed2004

[Treatment of severe systemic autoimmune diseases with autologous peripheral blood stem cell transplantation].

OBJECTIVE: To investigate the feasibility, efficacy and safety of high dose immunosuppressive therapy (HDIT) and autologous peripheral blood stem cell transplantation (PBSCT) with CD(34)(+) cell selection in patients with refractory and severe autoimmune diseases. METHODS: Twenty-one patients with SLE, RA, pSS, SSc or MCTD were enrolled in the study from 1999. Autologous haemopoietic stem cells were mobilized with CTX 3 approximately 4 g/m(2) and granulocyte colony stimulating factor (G-CSF). CD(34)(+) cells were selected by CliniMACS. After conditioning with CTX (200 mg/kg) and pig antithymocyte globulin (ATG, 90 mg/kg) or CTX (150 mg/kg) and total body irradiation (TBI, 4 approximately 6 Gy), the enriched CD(34)(+) cells were reinfused. RESULTS: All patients completed the mobilization and leukapheresis procedures successfully, and proceeded to receive conditioning and transplantation. Two patients died of complication related to transplantation, one is CMV infection, the other is severe pneumonia during the course of granulocyte deficiency. A MCTD patient completed the stem cell mobilization and died of severe pulmonary hypertension and heart failure before CD(34)(+) cells reinfusing. Two SLE patients relapsed in 26, 37 months respectively and a RA patient relapsed in 15 months after transplantation. Other patients got improved, with SLE-DAI score decreasing from 17 to 4 score and proteinuria decreasing from 6.7 g to 2.3 g in SLE patients; DAS28 score from 7.9 to 2.1 in RA patient; Symptom improved and lab results recovered in SS. CONCLUSION: High dose immunosuppressive therapy followed by autologous peripheral blood stem cell transplantation with CD(34)(+) cell selection is feasible and relative safe. Patients remain free from disease active and improved continuously. Some patients could relapse after transplantation. Long-term effect need to be further observed.

Arthritis, Rheumatoid↗
PubMed2004

[Clinical characteristics of propylthiouracil (PTU) induced antineutrophil cytoplasmic antibodies positive cases; analysis of a case of PTU-induced ANCA positive patients with hyperthyroidism].

OBJECTIVE: To study the clinical characteristics of propylthiouracil (PTU) induced antineutrophil cytoplasmic antibodies (ANCA) positive cases and increase the awareness of PTU induced ANCA positive vasculitis (APV). METHODS: The clinical data of nine cases with positive ANCA induced by PTU in Peking Union hospital since 2000 were analyzed and literature review was conducted. RESULTS: (1) Nine patients with hyperthyroidism, at a mean age of 33.1 (16 approximately 51), who were treated with PTU for a mean period of 32.4 months (3 approximately 84); (2) Sera from nine cases were ANCA positive, and autoantibodies from six tested cases could recognize not only MPO, but also PR3, HLE, BPI and LF; (3) Six cases with high titer perinuclear ANGA (pANCA) (> or = 1:1280) were diagnosed APV and all had renal involvement (five confirmed by renal biopsies), three cases with low titer pANCA (< or = 1:320) had little clinical manifestations of vasculitis; (4) Eight patients stopped taking PTU when positive ANCA were noted. One case with APV got remission after stopping PTU, the other three APV were treated with glucocorticosteroid and immunosuppressive agents at meanwhile. Only one patient kept taking PTU for eighteen months without an increased titer of ANCA. CONCLUSION: PTU could induce production of ANCA. High titer of ANCA might suggest existence of APV and the titer would be associated with status of APV. Early withdrawal of PTU and administration of glucocorticosteroid and immunosuppressive agents based on renal pathology will greatly improve the prognosis.

Adolescent↗
PubMed2004

[Anti-endothelial cell antibodies in systemic vasculitis: detection and correlation with disease activity].

OBJECTIVE: To investigate the prevalence of anti-endothelial cell antibodies (AECA) in systemic vasculitis and to assess the correlation between AECA and disease activity, and try to discuss the classification of AECA. METHODS: Cyto-ELISA with EA.hy926 and HMEC-1, two immortalized cell lines, as substrates, was applied to detect AECA in 122 cases of systemic vasculitis, including 43 cases of Behcet disease, 19 cases of Takayasu arteritis, 19 cases of Wegener's granulomatosis, 11 cases of microscopic polyangiitis, 9 cases of polyarteritis nodosa, 3 cases of Churg-Strause syndrome, 2 cases of giant cell arteritis and other 16 cases of which could not be classified clearly. Patients with SLE, RA, and fever of unknown origin, and normal persons were used as control groups. Then the associations of AECA to laboratory findings and clinical disease activity (scored by BVAS) were analyzed. Furthermore, the AECA value from the two different substrate cells were analyzed for correlation and difference. RESULTS: With either EA.hy926 or HMEC-1 as substrates, the AECA prevalence rates of systemic vasculitis (respectively 33.61% and 37.70%) were significantly higher than those of the normal and RA groups (less than 10%), and the prevalence of AECA in SLE (61.75%) was higher than that of systemic vasculitis (37.70%) when using HMEC-1 as substrates. AECA was found to correlate very well with ESR in 122 cases of systemic vasculitis and with BVAS in 40 cases of small systemic vasuculitides, including Wegener's disease, microscopic polyangiitis, Churg-Strause syndrome and so on. The pair AECA values with EA.hy926 and HMEC-1 as substrate cells were found to be correlated significantly, and the matching rate was 92.62%. CONCLUSION: Prevalence of AECA in systemic vasculitis is high. AECA indicates the clinical disease activity. As to the assumption of classification of AECA into antibodies against microvascular and macrovascular endothelial cells, further study need to be done to prove or disprove it.

Adult↗
PubMed2004

[Clinical analysis of 61 patients with antiphospholipid syndrome].

OBJECTIVE: To investigate the clinical manifestations, diagnosis and treatment of anti-phospholipid syndrome (APS). METHODS: 61 patients with defined APS admitted from Jan 1986 to Dec 2002 were analyzed retrospectively. RESULTS: 10 patients with primary APS and 51 patients with secondary APS were analyzed. Women were affected 3.1 times as that of men. 48 of the 51 (94.1%) patients with secondary APS were complicated with other autoimmune diseases, including 33 cases (64.7%) of systemic lupus erythematosus. Vascular thrombosis was presented in around 80.3% of the patients in this study. Thrombosis frequently involved the gastrointestinal system (21 cases, 22.6%), pulmonary system (19 cases, 20.4%), the cerebral vascular system (17 cases, 18.3%), lower limb deep venous system (16 cases, 17.2%), and infrequently coronary arteries or adrenal glands. The abnormal pregnancy rate in the 37 married women was 45.9%. The prevalence of anticardiolipin antibody (ACL) and lupus anticoagulant (LA) was 77.0% and 62.3% respectively. LA was associated with ACL. CONCLUSION: APS occurs most commonly among young women, is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with positive ACL or LA. Thrombosis frequently occurs in gastrointestinal system, pulmonary system, cerebral vascular system and deep venous system. The association between clinical features of APS and antiphospholipid antibody is significant. LA is a stronger risk factor for thrombosis and abnormal pregnancy than ACL. Antiplatelet with low-dosage aspirin and long-term anticoagulation are main therapeutics.

Adult↗
PubMed2004

[Cytophagic histiocytic panniculitis: a report of 6 cases with literature review].

OBJECTIVE: To study the clinical characteristics of cytophagic histiocytic panniculitis (CHP) and increase the understanding of CHP. METHODS: Clinical data of six cases with CHP in our hospital from 1994 were presented with literature review. RESULTS: (1) Six patients including five females, at a mean age of 21.8 year, suffered from the diseases for a mean period of 12.7 months; (2) The major clinical presentations included fever (6/6), subcutaneous nodules (6/6), splenomegaly (5/6) and hepatomegaly (4/6); The laboratory examinations showed elevated hepatic enzymes (4/6), coagulative dysfunction (2/6) and hemocytopenia (3/6); (3) The pathologic examinations revealed benign histiocytes that infiltrated the adipose tissues (6/6) and hemopieotic tissue (3/3), phagocytosing hemocytes; (4) Only one patient was treated with combined chemotherapy. CONCLUSIONS: CHP should be considered based on its unique clinical characteristics and would be diagnosed depending on pathology. The aggressive treatment of combined chemotherapy might improve the prognosis.

Adipose Tissue↗
PubMed2004

[BAY11-7082 and Lactacystein in CD154-induced NF-kappaB activation].

OBJECTIVE: To investigate the inhibition mechanisms of BAY11-7082 (IkappaB-alpha phosphorylation inhibitor) and Lactacystein (proteosome inhibitor) in CD154-induced NF-kappaB activation. METHODS: We used recombinant CD154 to stimulate EBV/LMP1 negative Ramos B cell and observed the effects of BAY11-7082 and Lactacystein in CD154-induced NF-kappaB luciferase activation, phosphorylation and degradation of IkappaB-alpha, phosphorylation of p65, and nuclear translocation of NF-kappaB subunits upon CD154 stimulation. RESULTS: Both BAY11-7082 and Lactacystein abrogated CD154-induced NF-kappaB luciferase activation in Ramos cells. While CD154-induced phosphorylation of p65, phosphorylation and degradation of IkappaB-alpha, and nuclear translocation of p50, p65, and c-Rel were all blocked by BAY11-7082; Lactacystein only inhibited degradation of IkappaB-alpha and p65 nuclear translocation. CONCLUSION: BAY11-7082 and Lactacystein inhibit CD154-induced NF-kappaB activation through different mechanisms.

Acetylcysteine↗
PubMed2004

[Human cartilage glycoprotein 39 mRNA expression in peripheral blood and synovium mononuclear cells in rheumatoid arthritis].

OBJECTIVE: To investigate the expression of human cartilage glycoprotein 39 (HC gp-39) in peripheral blood mononuclear cells (PBMC) and synovium of rheumatoid arthritis (RA) patients. METHODS: Levels of HC gp-39 mRNA were detected by reverse transcription-polymerase chain reaction in PBMC of 31 patients with RA, 6 with osteoarthritis (OA), 10 with spondylarthropathy (SpA), 5 with systemic lupus erythematosus (SLE), and of 10 healthy controls. Levels of HC gp-39 mRNA were also detected in synovium of 7 patients with RA and 5 with OA. The expression of HC gp-39 was semi-quatificated by HC gp-39/tubulin ratio. RESULTS: HC gp-39 mRNA expression in PBMC was increased in RA patients (the HC gp-39/tubulin ratio was 0.8690 +/- 0.5240), compared with OA (P = 0.024), SpA (P = 0.049), SLE (P = 0.043) and with healthy control subjects (P = 0.033). There were no statistically significant differences among OA, SpA, SLE and healthy controls. The level of HC gp-39 mRNA expression in RA synovium was also significantly higher than the level found in OA (P = 0.04). CONCLUSIONS: HC gp-39 mRNA was obviously overrepresented in RA patients PBMC and synovium. These data support a possible pathogenic role of HC gp-39, as a candidate autoantigen, in the autoimmune response of RA.

Adipokines↗
PubMed2003

[Expression of chemokine in the labial glands of patients with Sjogren's syndrome].

OBJECTIVE: To investigate the expression of chemokine RANTES (regulated upon activation, normal T cell expressed and secreted) and macrophage inflammatory protein 1alpha (MIP-1alpha) in the labial glands of patients with Sjogren's syndrome (SS) and discuss their involvement in SS etiopathology. METHODS: Immunohistochemistry was used to examine the expression of RANTES and MIP-1alpha in the specimens of labial gland of 14 cases of primary SS, 7 cases of secondary SS (sSS), and 8 cases of controls, including maxillofacial injury and lip cyst. RESULTS: The expression rate of RANTES was 86% (12/14) in the pSS group and 71% (10/14) in the sSS group, and was 0 in the control group (P < 0.01). The expression rate of MIP-1alpha was 86% (5/7) in the pSS group, 71% (5/7) in the sSS group, and 25% (2/8) in the control group (P > 0.05). The RANTES and MIP-1alpha were expressed in the cytoplasm of ductal epithelium and part of infiltrated lymphocytes. The positive expression of RANTES was more evident than that of MIP-1alpha. CONCLUSION: RANTES and MIP-1alpha may attract the circulating lymphocytes towards inflammation site of labial gland so as play a crucial role in the pathogenesis of SS etiopathology.

Adult↗
PubMed2003

[A preliminary study on the treatment of severe autoimmune disease by autologous peripheral CD(34)(+) cell transplantation].

OBJECTIVE: To evaluate the feasibility of autologous peripheral CD(34)(+) cell transplantation for the treatment of severe autoimmune disease. METHODS: Ten patients received mobilized and purified CD(34)(+) cells transplantation. The mobilization regimen was CTX plus rhG-CSF and the CD(34)(+) cells were selected by CliniMACS. (1.98 +/- 0.95) x 10(8) CD(34)(+) cells were obtained. The purity of CD(34)(+) cells was (91.4 +/- 10.6)% and the recovering rate was (60.5 +/- 19.8)%. The conditioning regimens were CTX (200 mg/kg) plus ATG (90 mg/kg) or CTX (150 mg/kg) plus TBI (4 - 6 Gy). (2.14 +/- 1.05) x 10(6)/kg CD(34)(+) cells were infused. The time of ANC >or= 0.5 x 10(9)/L was 8.6 +/- 2.5 days, and platelet >or= 20 x 10(9)/L was 9.0 +/- 5.2 days. After the hematopoietic recovery, the levels of CD(3)(+) T cell, CD(19)(+) B cells and CD(16)(+)CD(56)(+) NK cells were all below that of pre-transplantation. The main transplant-related complication was CMV infection. The transplant-related mortality was 2/10. All patients who survived showed improvement of the disease with DAI score decreasing from 17 to 4 in systemic lupus erythematosus patients, DAS 28 score from 6.4 to 1.8 in rheumatoid arthritis patients. CONCLUSION: The result suggests that autologous peripheral CD(34)(+) cell transplantation is an alternative choice for the treatment of severe autoimmune disease. The short-term outcome is satisfying.

Adolescent↗
PubMed2003

[Abnormal interferon-inducible protein-10 expression in the labial glands of patients with Sjogren's syndrome].

OBJECTIVE: To investigate whether interferon-inducible protein 10 (IP-10) is involved in the inflammatory process of the labial gland of patients with Sjogren's Syndrome (SS). METHODS: Forty-nine patients performed labial gland biopsy, the number of lymphocytes in the biopsy tissues was calculated and the IP-10 was detected by the methods as following: 39 biopsied labial tissues were examined by RT-PCR, among them, 21 were from primary SS, 5 from secondary SS and 13 from other diseases. With RT-PCR, the IP-10 and beta-actin were co-amplified with specific primers. The gel-fractioned and ethidium bromide amplification products were then analyzed by densitometry. The expression of IP-10 was semi-quantificated by IP-10/beta-actin ratio. Twenty-one samples were examined by immunohistochemistry with specific goat anti-IP-10 antibody, 10 of them from primary SS, 3 from secondary SS, 8 from other diseases. 11 out of 21 samples were examined by both RT-PCR and immunohistochemistry. RESULTS: The expression of IP-10 mRNA was significantly up-regulated in labial glands of patients with SS compared with other diseases (IP-10/beta-actin ratio was 0.329 +/- 0.157 vs 0.099 +/- 0.059, P < 0.01). The number of lymphocyte infiltration foci in labial glands of patients with SS correlated to the IP-10/beta-actin ratio (r = 0.657, P < 0.05). Ductal epithelial cells and some of the infiltrating lymphocytes were stained by anti-IP-10 antibody by immunohistochemistry in 8 of the primary SS (8/10), all of the secondary SS (3/3) and one with primary biliary sclerosis (1/8). The expression of IP-10 protein detected by immunohistochemistry was consistent with that of mRNA detected by RT-PCR. CONCLUSIONS: IP-10 is abnormally highly expressed in the labial glands of patients with SS and positively relates to the lymphocyte infiltration. It thus suggests chemokine IP-10 may be one of the important molecules attracting the lymphocytes to the minor salivary glands to form the lymphocytic foci of Sjogren's Syndrome.

Adult↗
PubMed2002

[Pulmonary thromboembolism in systemic lupus erythematosus: clinical analysis of 11 cases].

OBJECTIVE: To investigate the diagnosis and therapy of systemic lupus erythematosus (SLE) patients with pulmonary thromboembolism (PTE). METHODS: 11 hospitalized cases were reviewed retrospectively in PUMC Hospital during January 1984-July 2001. RESULTS: All 11 cases were suffered from severe active lupus with PTE. The SLE-DAI (SLE-disease active index) was 21.9 +/- 4.9. 7 cases had first onset of progressive Raynaud phenomenon. Anti-RNP antibody was positive in 73% of the cases. Echocardiogram revealed medium-severe pulmonary hypertension. When PTE was found, while 6 cases had started with smaller to medium dose of prednisone treatment, which was 20-30 mg/d, and other 4 cases received no prednisone. Only 1 received large dose of prednisone and immunosuppressor. Large dosage of prednisone, immunosuppressor with or without anticoagulant were given to those 6 and 4 patients after final diagnosis, respectively. 6 of 7 cases showed relieved Raynaud phenomenon while 4 cases hemoptysis were disappeared, echocardiogram had confirmed that pulmonary artery pressure decreased in 4 cases. [(31.7 +/- 12.4) mmHg]. 5 cases survived, 3 were dead and 3 failed to be followed up. CONCLUSIONS: Patients of SLE with PTE are liable to be misdiagnosed or missed-diagnosed, The risk factors are active-SLE, progressive Raynaud phenomenon, and symptoms of thromboembolism, positive anti-RNP antibody and mild-medium pulmonary artery hypertension. Combined therapy of present available measures like large dose of prednisone, immunosuppressors and anticoagulant are highly recommended.

Adult↗
PubMed2002

[Follow-up studies in polymyalgia rheumatica and temporal arteritis].

OBJECTIVE: To analyze the clinical course and duration of therapy in 28 patients with polymyalgia rheumatica (PMR) and/or temporal arteritis (TA) for identifying factors that influence prolonged steroid use and relapses. METHODS: 28 cases of PMR and/or TA diagnosed from 1992 to 2001 were retrospectively studied in PUMC hospital. Patients were grouped according to the absence or presence of corticosteroid resistant and relapses. RESULTS: Of 28 patients, 22 had pure PMR, 3 had both PMR and TA and 3 had pure TA. 15 patients received corticosteroid therapy and 13 had both corticosteroid and immunosuppressor therapy. The median duration was (25.5 +/- 24.0) months. Increase of white blood cell level and higher baseline erythrocyte sedimentation rate (ESR) were significant risk factors associated with corticosteroid resistant (P < 0.01). Quicker reduction of corticosteroid dose was associated with relapse (P < 0.05). CONCLUSIONS: Patients with increase of white blood cell level and higher baseline erythrocyte sedimentation rate (ESR) are more likely to be resistant to corticosteroid therapy. Quicker reduction in corticosteroid is more likely to relapse. Immunosuppressor therapy should be added to patients who has corticosteroid resistant, and relapse or PMR associated with TA.

Aged↗